With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.
News & Analysis: Myovant Sciences Ltd.
The results were consistent with a pair of shorter studies of the combination treatment.
Shares swung wildly as investors tried to guess at the long-run prospects of promising new drug treatments for prostate cancer.
Relugolix has the potential to be a blockbuster drug in two markets, but it faces competition in both.
The rally continues.
Find out what made these stocks climb on a mixed day for the market.
The clinical-stage biotech announced wonderful phase 3 results.
The company announced the pricing of a public stock offering, but investors found a silver lining.
Do these under-the-radar stocks deserve a spot in your growth stock portfolio?